Wang Mei, Holbrook Anne, Lee Munil, Liu Jiayu, Leenus Alvin, Chen Nora, Mbuagbaw Lawrence, Thabane Lehana
Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Clinical Pharmacology & Toxicology, Research Institute, St Joseph's Healthcare Hamilton, 50 Charlton Avenue East, Hamilton, ON, L8N 4A6, Canada.
J Thromb Thrombolysis. 2020 Oct;50(3):697-714. doi: 10.1007/s11239-020-02056-0.
Oral anticoagulants (OACs) are high alert medications and require high-quality management to optimize health outcomes. The objective of this scoping review was to identify barriers and facilitators (B&Fs) associated with the quality of OAC management. We searched MEDLINE, EMBASE, and CINAHL databases until July 12, 2018, and cross-referenced the bibliographies of the retrieved studies. We included quantitative and qualitative studies that assessed B&Fs to OAC management. The study selection and data extraction processes were performed in duplicate. Analyses included measuring the prevalence of reported B&Fs from studies reporting quantitative data, identifying B&Fs in narrative analyses, and identifying their impact on important outcomes of OAC management. B&Fs were coded and aggregated to higher-level themes using a consensus approach. Factors were described as "key" if they were statistically associated with important outcomes in a randomized trial or observational study. We included 62 studies-three randomized clinical trials (RCTs), 46 observational studies (cross-sectional studies, cohort studies, and case-control studies), 11 qualitative studies, and two mixed-methods studies. Factors identified could be grouped into four themes-therapy-related, patient-related, healthcare provider-related, and health system-related. Key barriers to optimal OAC management were mostly patient-related, whereas interventions focused on education or implementing protocols were shown through RCTs to be effective at improving knowledge scores of OAC patients. While multiple barriers and some facilitators were identified in this review, none was proven to be associated with clinical outcomes. With this in mind, individual physicians may wish to address the key barriers in their practice as a quality improvement initiative but system-wide or policy changes should await high-quality evidence. Future trials should address these factors.Systematic review registration: PROSPERO CRD42017069043.
口服抗凝剂(OACs)是高警示药物,需要高质量管理以优化健康结局。本范围综述的目的是确定与OAC管理质量相关的障碍和促进因素(B&Fs)。我们检索了MEDLINE、EMBASE和CINAHL数据库直至2018年7月12日,并对检索到的研究的参考文献进行交叉引用。我们纳入了评估OAC管理的B&Fs的定量和定性研究。研究选择和数据提取过程由两人独立进行。分析包括测量报告定量数据的研究中报告的B&Fs的患病率,在叙述性分析中识别B&Fs,并确定它们对OAC管理重要结局的影响。使用共识方法对B&Fs进行编码并汇总为更高级别的主题。如果因素在随机试验或观察性研究中与重要结局存在统计学关联,则将其描述为“关键”因素。我们纳入了62项研究——3项随机临床试验(RCTs)、46项观察性研究(横断面研究、队列研究和病例对照研究)、11项定性研究和2项混合方法研究。确定的因素可分为四个主题——治疗相关、患者相关、医疗保健提供者相关和卫生系统相关。最佳OAC管理的关键障碍大多与患者相关,而通过RCTs表明,侧重于教育或实施方案的干预措施在提高OAC患者的知识得分方面是有效的。虽然在本综述中识别出了多个障碍和一些促进因素,但没有一个被证明与临床结局相关。考虑到这一点,个体医生可能希望在其实践中解决关键障碍作为质量改进举措,但全系统或政策层面的改变应等待高质量证据。未来的试验应解决这些因素。系统综述注册:PROSPERO CRD42017069043。